Aggarwal, C., Csoszi, T., Szalai, Z., Bar, J., Peled, N., Cho, B. C., Kim, Y. J., Kowalski, D. M., Nadal, E., Niu, J., Gainor, J. F., Carbone, D. P., Dragnev, K. H., Chen, K., Sternberg, D. W., Zhao, B., Zhou, H., Namakydoust, A., Velcheti, V. (2025). KEYMAKER-U01 substudy 01A: Phase 1/2 study of pembrolizumab plus ifinatamab deruxtecan (I-DXd) or patritumab deruxtecan (HER3-DXd) with or without chemotherapy in untreated stage IV non–small-cell lung cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps8652